Does a recent US Food and Drug Administration’s (FDA’s) decision to allow pharmacists to prescribe Pfizer’s COVID-19 antiviral indicate that this idea could be applied more broadly post-pandemic?
In an article from Pharma Intelligence’s Pink Sheet, partner Kathleen Sanzo opined that federal law likely would have to be changed to allow that type of behind-the-counter access—but said there may be more interest if Paxlovid prescribing is successful.
Ultimately, reimbursement for the pharmacists' work will determine whether the practice can flourish.
“If they can take care of the money piece of this you may have a better chance of success,” Kathy said.
Read the full Pink Sheet article >>
Subscription may be required.